Goals of EBP Phase 2 is to complete high-quality reference genome sequencing for 150,000 species within
five years, covering at least 50% of known eukaryotic genera, while prioritizing species of significant
value to ecological conservation, food security, disease prevention and control, and the biotech industry.
Upon completion of this phase, EBP will encompass approximately one-tenth of known eukaryotic biodiversity
on Earth, laying the foundation for Phase 3.
EBP2 Progress
61 / 60
CLASS
102%
185 / 238
ORDER
78%
507 / 879
FAMILY
58%
1,566 / 6,701
GENUS
24%
6,975
SPECIES
8,263
NCBI GENUS
Core QC metrics
Minimum
Median
Maximum
Average
Genome size
330.78Kb
33.81Mb (n=6,974)
2.05Gb
38.36Mb
Contig N50
130
183.88Kb (n=6,974)
37.09Mb
813.90Kb
Scaffold N50
133
278.41Kb (n=6,961)
60.21Mb
1.06Mb
GC percentage (%)
16.5
49 (n=6,974)
68.5
48
Classarrow_upward
arrow_upwardNumber of EBP2 target genus
arrow_upwardNumber of sequenced genus
arrow_upwardNumber of pending genus
arrow_upwardCoverage
sordariomycetes
1,383
0
1,383
0%
dothideomycetes
1,329
0
1,329
0%
agaricomycetes
1,208
0
1,208
0%
lecanoromycetes
653
0
653
0%
leotiomycetes
502
0
502
0%
Records per page:
5
arrow_drop_down
1-5 of 60
Implementation Roadmap
Collect samples from 300,000 species worldwide
Select 150,000 of these for high-quality reference genome sequencing
Total core project investment of approximately US$1.1 billion
Global Division of Labor
EBP2 will be jointly advanced by multiple regional centers, with plans to establish approximately 25
regional nodes worldwide. Each node will collect samples from approximately 12,000 species and complete the
sequencing and assembly of approximately 6,000 species.
Group Photo at the EBP2 Launch Meeting (May 2026, Canada)
For the EBP China Center partnership recruitment initiative and detailed information, please see
this page.